- Home
- Equipment
- usa new york
- protein targeted
Show results for
Refine by
Protein Targeted Equipment Supplied In Usa New York
6 equipment items found
Manufactured by:CD BioSciences based inShirley, NEW YORK (USA)
Full length Clone DNA of Rhesus tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, beta polypeptide with C terminal His ...
Manufactured by:CD BioSciences based inShirley, NEW YORK (USA)
The 14-3-3 family of proteins plays a key regulatory role in signal transduction, checkpoint control, apoptotic and nutrient-sensing pathways. 14-3-3 proteins are highly conserved and ubiquitously expressed. There are at least seven isoforms, β, γ, ε, σ, ζ, τ, and η that have been identified in ...
Manufactured by:CD BioSciences based inShirley, NEW YORK (USA)
The 14-3-3 family of proteins plays a key regulatory role in signal transduction, checkpoint control, apoptotic and nutrient-sensing pathways. 14-3-3 proteins are highly conserved and ubiquitously expressed. There are at least seven isoforms, β, γ, ε, σ, ζ, τ, and η that have been identified in ...
Manufactured by:CD BioSciences based inShirley, NEW YORK (USA)
The 14-3-3 family of proteins plays a key regulatory role in signal transduction, checkpoint control, apoptotic and nutrient-sensing pathways. 14-3-3 proteins are highly conserved and ubiquitously expressed. There are at least seven isoforms, β, γ, ε, σ, ζ, τ, and η that have been identified in ...
Manufactured by:Calder Biosciences, Inc. based inBrooklyn, NEW YORK (USA)
Calder’ protein engineering technology is based on targeted di-tyrosine (DT) crosslinking, which allows proteins to be locked in desired shapes. We apply this methodology to engineer novel vaccines that are locked in the shapes that elicit the most potently protective antibody ...
by:AptaMatrix, Inc. based inSyracuse, NEW YORK (USA)
Aptamers are DNA/RNA molecules that have affinities for their targets similar to antibodies. Aptamers have shown great potential to replace antibodies in biosensors, point-of-care diagnostics, therapeutics, and all of the areas currently dominated by antibodies. Once aptamers have been identified, they can be produced for less than 10% of the cost of antibodies. The commercial value of antibodies ...